1 |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2 |
BROWN P, INABA H, ANNESLEY C, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(1): 81-112.
|
3 |
PUI C H, YANG J J, HUNGER S P, et al. Childhood acute lymphoblastic leukemia: progress through collaboration[J]. J Clin Oncol, 2015, 33(27): 2938-2948.
|
4 |
HUNGER S P, RAETZ E A. How I treat relapsed acute lymphoblastic leukemia in the pediatric population[J]. Blood, 2020, 136(16): 1803-1812.
|
5 |
MITTAL R, PATEL K, MITTAL J, et al. Association of PRPS1 mutations with disease phenotypes[J]. Dis Markers, 2015, 2015: 127013.
|
6 |
TAIRA M, IIZASA T, YAMADA K, et al. Tissue-differential expression of two distinct genes for phosphoribosyl pyrophosphate synthetase and existence of the testis-specific transcript[J]. Biochim Biophys Acta, 1989, 1007(2): 203-208.
|
7 |
LI S, LU Y C, PENG B Z, et al. Crystal structure of human phosphoribosyl pyrophosphate synthetase 1 reveals a novel allosteric site[J]. Biochem J, 2007, 401(1): 39-47.
|
8 |
AL-MAAWALI A, DUPUIS L, BLASER S, et al. Prenatal growth restriction, retinal dystrophy, diabetes insipidus and white matter disease: expanding the spectrum of PRPS1-related disorders[J]. Eur J Hum Genet, 2015, 23(3): 310-316.
|
9 |
DE BROUWER A P, VAN BOKHOVEN H, NABUURS S B, et al. PRPS1 mutations: four distinct syndromes and potential treatment[J]. Am J Hum Genet, 2010, 86(4): 506-518.
|
10 |
DE BROUWER A P, WILLIAMS K L, DULEY J A, et al. Arts syndrome is caused by loss-of-function mutations in PRPS1[J]. Am J Hum Genet, 2007, 81(3): 507-518.
|
11 |
KIM H J, SOHN K M, SHY M E, et al. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (CMTX5)[J]. Am J Hum Genet, 2007, 81(3): 552-558.
|
12 |
LI B S, LI H, BAI Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL[J]. Nat Med, 2015, 21(6): 563-571.
|
13 |
PINKEL D, HERNANDEZ K, BORELLA L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia[J]. Cancer, 1971, 27(2): 247-256.
|
14 |
SOMAZU S, TANAKA Y, TAMAI M, et al. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells[J]. J Cell Mol Med, 2021, 25(22): 10521-10533.
|
15 |
PUI C H. Recent research advances in childhood acute lymphoblastic leukemia[J]. J Formos Med Assoc, 2010, 109(11): 777-787.
|
16 |
BASSAN R, HOELZER D. Modern therapy of acute lymphoblastic leukemia[J]. J Clin Oncol, 2011, 29(5): 532-543.
|
17 |
RELLING M V, HANCOCK M L, BOYETT J M, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia[J]. Blood, 1999, 93(9): 2817-2823.
|
18 |
KARRAN P, ATTARD N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer[J]. Nat Rev Cancer, 2008, 8(1): 24-36.
|
19 |
BHATIA S, LANDIER W, SHANGGUAN M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group[J]. J Clin Oncol, 2012, 30(17): 2094-2101.
|
20 |
INABA H, MULLIGHAN C G. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539.
|
21 |
LI B S, BRADY S W, MA X T, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia[J]. Blood, 2020, 135(1): 41-55.
|